DOC

Business profile & competitive position

Healthpeak Properties, Inc. is a Real Estate sector company classified in the REIT - Healthcare Facilities industry. Through its operating subsidiary, Healthpeak OP, it owns, operates, and develops U.S. healthcare real estate focused on healthcare discovery and delivery. As of December 31, 2025, its portfolio held interests in 689 properties split among outpatient medical buildings and hospitals, lab/life science buildings, and senior housing, plus non-reportable assets such as loans receivable, a preferred equity investment, and three other properties.

The financial profile is more capital-light on reported net income than a typical operating company. Net margin is 8.6% and return on equity is 3.3%. Those figures are low relative to many non-REIT businesses, but that is consistent with healthcare REIT economics: real estate is asset-heavy, depreciation is large, and equity is broad. A 3.3% ROE does not point to a wide moat if judged purely on accounting earnings, yet the portfolio’s hospital-campus adjacency and long-term triple-net lease structures can create durable tenant relationships. Around 79% of outpatient medical buildings are on or adjacent to hospital campuses, about 96% are affiliated with hospital systems, and about 72% of outpatient leased square feet is triple-net leased, which generally shifts operating-cost risk to tenants. The lab portfolio is about 89% triple-net leased and concentrated in San Francisco (59% of square feet), Boston (22%), and San Diego (17%). Those leasing structures are the company’s real competitive foundation; the reported margin and ROE are simply REIT accounting outputs rather than a full cash-flow picture.

Financial posture

Healthpeak’s current market capitalization is $13.4 billion. It trades at a P/E of 55.7, carries a net margin of 8.6%, posts an ROE of 3.3%, and has a beta of 0.99. The P/E looks elevated unless viewed through the lens of funds from operations or net asset value, common REIT valuation yardsticks. A beta of 0.99 implies the stock has moved roughly in line with the broader market, neither defensive nor aggressive on a systematic-risk basis.

At the current price of $19.505, the stock is just below its 50-day exponential moving average of $19.67, with an RSI of 53.2, a neutral reading. The company does not carry an explicit debt figure in this snapshot, but the 10-K strategic context describes a targeted investment-grade balance sheet, ample liquidity, and primarily long-term fixed-rate debt with staggered maturities to limit interest-rate and refinancing risk. That posture matters because a healthcare REIT’s ability to finance properties cheaply is as important as its lease rollovers.

Strategic priorities & outlook

Healthpeak’s most recent 10-K filing outlines four operational priorities. The first is to own, operate, and develop high-quality outpatient medical, lab, and senior housing real estate while managing the portfolio for long-term risk-adjusted returns and dividend growth. The second is to keep a strong investment-grade balance sheet with ample liquidity and mostly long-term fixed-rate debt, staggered maturities included, to reduce both interest-rate and refinancing risk. The third is internal growth: working with tenants on space and capital needs, replacing tenants at favorable terms, extending or modifying leases before expiration, and providing property management that encourages renewals, expansions, and relocations. The fourth is to complete the proposed Janus Living IPO in the first half of 2026 by contributing its 34-community senior housing portfolio and retaining a substantial majority ownership interest while serving as external manager.

The 2025 segment Adjusted NOI figures show where value is generated: outpatient medical contributed $795.843 million, lab contributed $567.358 million, and senior housing contributed $176.741 million. Outpatient medical is the earnings engine, with lab a meaningful second contributor and senior housing the smallest but still strategically important as the Janus Living spin candidate. In January 2026, Healthpeak acquired the remaining 46.5% interest in its SWF SH JV, bringing its ownership of those 19 senior housing properties to 100%. That step looks like a portfolio-positioning move ahead of the planned IPO.

Macro & geopolitical exposure

As a healthcare facilities REIT, Healthpeak is exposed to macro forces that affect real estate capital markets, tenant demand, and reimbursement. Interest-rate levels are the most direct macro variable: higher rates raise the cost of refinancing and acquisition capital and can compress cap rates, lowering property valuations. Inflation affects operating costs, but the company’s heavy use of triple-net leases passes many of those costs through to tenants, especially in outpatient and lab.

Regulation and reimbursement are sector-level risks. Healthcare tenants depend on Medicare, Medicaid, and private insurance payment schedules; any change in reimbursement rules can alter tenant credit quality and demand for outpatient, lab, or senior housing space. Trade policy is a smaller direct concern for a domestic REIT, though construction-material costs and equipment prices can be influenced by tariffs or supply-chain disruptions. Currency is not a meaningful factor because the portfolio is U.S.-only. Regional economic health matters because lab space is concentrated in San Francisco, Boston, and San Diego, while outpatient medical depends on hospital-system footprints. A slowdown or oversupply in those metros would be felt more acutely than in a diversified national portfolio.

Recent developments

The October 2026 news cycle has centered on earnings and dividend themes. On October 19, SteelPeak Wealth LLC raised its stake in Healthpeak Properties, according to defenseworld.net. On October 20, Seeking Alpha published “What To Watch This REIT Earnings Season,” placing Healthpeak among the names under scrutiny. On October 22, another Seeking Alpha headline, “Monthly-Paid Dividends: 21 Ideal ‘Safer’ October Dogs To Buy,” included the company in a dividend-income list. On October 29, Zacks asked, “What’s in the Cards for Healthpeak Properties This Earnings Season?” That sequence suggests the market is focused on the upcoming report, income generation, and incremental institutional accumulation.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, Healthpeak has beaten earnings estimates four times, a 50% beat rate. The average earnings surprise across those quarters is 18.2%, and the average five-day post-earnings move has been 2.24% to the upside. That average, however, masks real inconsistency. The last four reports show why post-earnings drift cannot be taken for granted even on beats.

For the quarter reported August 4, 2026, actual EPS came in at $0.08 versus an estimate of $0.02815, a 184.2% positive surprise. The stock rose 0.79% the next day but fell 5.13% over the following five sessions. On May 5, 2026, actual EPS of $0.28 crushed the $0.05276 estimate, a 430.7% surprise, and the stock surged 18.11% the next day and 19.81% over the next five days. The February 2, 2026 report missed: actual EPS of $0.16 versus an estimate of $0.45, a -64.4% surprise, with a -2.78% next-day drop and -0.47% five-day drift. Then on October 23, 2025, the company reported EPS of -$0.17 versus an estimate of $0.06, a -383.3% surprise; the stock actually rose 1.19% the next day but sank 5.23% over the following week.

The takeaway is that Healthpeak’s beat quarters do not automatically translate into sustained upward drift. The May 2026 report showed powerful follow-through, but the August 2026 beat was followed by a five-day decline. The next report is scheduled for November 2, 2026, after the market close, with the consensus EPS estimate at $0.06355. The average historical surprise and average positive five-day drift provide context, yet the wide dispersion of individual reactions means the post-earnings path has been, and likely will remain, uneven.

For a fuller picture of how analysts are modeling the upcoming Janus Living IPO, balance-sheet trajectory, and NAV-based valuations, explore the full institutional verdict on the ticker page.